TG Therapeutics, Inc. (TGTX) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Biotechnology
Sell if holding. Momentum 2.3/10 is below the 5.0 floor at $34.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole source of supply.
TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with BRIUMVI (ublituximab-xiiy) as its FDA-approved treatment for relapsing forms of multiple sclerosis, launched in the U.S. in January 2023 and in Europe via Neuraxpharm. Revenue derives from U.S. net... Read more
Sell if holding. Momentum 2.3/10 is below the 5.0 floor at $34.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole source of supply. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 4d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRIUMVI10-K Item 1A: 'We contract with third parties for the manufacture and testing of BRIUMVI for commercial supply, as well as all of our clinical product supply'
- HIGHSuppliersole source of supply10-K Item 1A: 'The third parties upon whom we rely for the supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance, drug product, and other materials used in our drug candidates are our sole source of supply'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.3/10 is below the 5.0 floor at $34.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole source of supply. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $32.06. Score 5.5/10, moderate confidence.
Take-profit target: $38.78 (+13.4% upside). Prior stop was $32.06. Stop-loss: $32.06.
Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole source of supply; Earnings in 4 days (event risk).
TG Therapeutics, Inc. trades at a P/E of 12.1 (forward 14.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
15 analysts cover TGTX with a consensus score of 3.9/5. Average price target: $45.
What does TG Therapeutics, Inc. do?TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with BRIUMVI (ublituximab-xiiy) as its...
TG Therapeutics is a commercial-stage biotech focused on B-cell diseases, with BRIUMVI (ublituximab-xiiy) as its FDA-approved treatment for relapsing forms of multiple sclerosis, launched in the U.S. in January 2023 and in Europe via Neuraxpharm. Revenue derives from U.S. net product sales of BRIUMVI and milestone payments/royalties from ex-U.S. commercialization.